Medipost
CompanySouth KoreaFounded 2000
Medipost develops one asset, in phase 3 (CARTISTEM in knee cartilage defects). Mostly cell therapy acting on inflammation and stem cell maintenance; based in South Korea, founded in 2000.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 0
- Signals
Pipeline
1Allogeneic umbilical cord blood-derived mesenchymal stem cells with hyaluronate hydrogel to regenerate cartilage and reduce inflammation
Phase 3, Cell therapy, Inflammation, Stem cell maintenance, knee cartilage defects
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1
- Signals1
- Integrity notices1
- Similar companies6